RespireRx Pharmaceuticals Inc (RSPI): Open question: Assuming CX-717 is dead...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	14
Posts	2972
Boards Moderated	0
Alias Born	07/19/2006

haysaw

Re: None

Thursday, 12/14/2006 2:15:07 PM

Thursday, December 14, 2006 2:15:07 PM

Open question:
Assuming CX-717 is dead for ADHD (and hoping it is still alive for AD), what are some realistic possibilities going forward?

What I'm getting at is:
Could they determine what caused the histo finding, modify the chemical make-up, and "re-start" the program with the new version? Is this reasonable? Plausible? Pointless? Expensive?
After all, wasn't CX-717 "tweaked" from CX-701?

Any response would be appreciated?

Curtis

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RSPI News

Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM